atepeq/tico19 huggingface dataset:
about how long have these symptoms been going on?
kusan tsawon lokacin ne waɗannan alamun ke gudana?
and all chest pain should be treated this way especially with your age
kuma ya kamata a yi jiyya ga duk ciwon ƙirji ta wannan hanyar, musamman saboda shekarun ku
and along with a fever
kuma tare da zazzabi
and also needs to be checked your cholesterol blood pressure
sannan kuma yana bukatar a binciki hawan jini na cholesterol
and are you having a fever now?
kuma kuna da zazzabi yanzu
and are you having any of the following symptoms with your chest pain
kuma ko kuna jin wasu alamomin wadanan tare da ciwon kirjin ka
and are you having a runny nose?
kuma kuna fama da zubar da majina daga hanci?
and are you having this chest pain now?
kuma kuna jin zafin wannan kirji yanzu?
and besides do you have difficulty breathing
kuma bayan haka kuna samun wahalar yin numfashi
and can you tell me what other symptoms are you having along with this?
kuma zaku iya fada mini wasu nau'ikan cututtukan da kuke da su tare da wannan?
and does this pain move from your chest?
kuma wannan zafin yana motsawa daga kirjin ka?
and drink lots of fluids
kuma ku dinga shan ruwa mai yawa
and how high has your fever been
kuma yaya ne zafin zazzabin yake?
and i have a cough too
kuma ina da tari ma
and i have a little cold and a cough
kuma ina da sanyi kadan da tari
and i'm really having some bad chest pain today
kuma ina fama da mummunan ciwon kirji a yau
and is this the right time for your hay fever
kuma wannan shine lokacin da ya dace da zazzabin ku
and it get the chest pain
kuma yana jin zafin kirji
and i think i have a little bit of a fever
kuma ina tsammanin ina da zazzabi kaɗan
and i want you to describe where the chest pain is
kuma ina so ka bayana inda ciwon kirjin yake
and she is sorta have the same symptoms
kuma ita ma kamar tana da alamomin cutar
and tell me what symptoms are you having now?
kuma fada min wadanne alamomin cuta ka ke da su yanzu?
and they're having some fevers as well
kuma suna da ciwon zazzabi shima
and with your history of diabetes
kuma tare da tarihin ciwon sukari
and you know it feels like my chest is like gonna crush
Kuma ka san yadda yake ji kirjina kamar zai murkushe
and you know people cough on me all the time
kuma ka san mutane suna tari ko da yaushe a kai na
and you're having chest pain
kuma kana fama da ciwon kirji
and your symptoms do not go away in five days
kuma alamomin cutar ku ba su barin ku cikin kwanaki biyar
and you said this is a pressure in your chest
kuma kun ce wannan matsin lamba ne a kirjin ku
anyone in the family have a heart problem heart disease heart attack high cholesterol high blood pressure
akwai wani a danginku dake da matsalar zuciya ko cutar zuciya ko ciwon zuciya ko idan daskararren maiƙon cholesterol ya yi sama ko hawon jini?
any other symptoms or problems that you notice with the muscle aches?
akwai kuma wasu alamomin cututtuka ko matsaloli da kuka lura da ciwon ƙwayar tsokar?
any sharp pain on your left side of your chest?
ko akwai ciwo sosai a kirjin ku na bangaren hagu?
are there other people sick as you at home with your same symptoms?
akwai wasu mutanen da ba su da lafiya kamar yadda kuke a gida tare da alamomin ku iri ɗaya?
are you having any difficulty breathing now
ko kana fuskantar wahalar numfashi yanzu
are you having any other symptoms?
shin kana da wasu alamomi ciwo?
are you having any shortness of breath?
kana jin wani ƙarancin numfashi?
are you still having the chest pain
shin har yanzu kana jin ciwo a kirjinka
because this is flu season
sabo da wannan lokacin mura ne
besides the diabetes do you have other problems or important diseases?
ban da ciwon suga shin kuna da wasu matsaloli ko mahimman cututtuka?
but also we shouldn't be put aside for the heart cardiac origin chest pain
amma kuma bai kamata a sanya mu ba a gefe don ciwon kirjin zuciya
but a more important problem now is this chest pain
amma matsala mafi mahimmanci yanzu shine wannan ciwon kirji
but if you have the cough
amman idan ka na da tarin
but i have difficulty breathing
amma ina da wahalar numfashi
but i know lot of people cough on me
amman na san mutane da yawa wanda suke min tari
but we need to treat every chest pain with the utmost seriousness
amma ya kamata mubu dauke kowane ciwon kirji da matuƙar mahimmanci
but you're breathing all right right now right?
amman yanzu kuna ninfashi lafiya haka ko?
'cause of this chest pain i totally forgot
na manta da sanadin wannan ciwon kirji
'cause they're having a cough
domin suna da tari
does it feel like somebody squeezing your chest
shin kana jin kamar wani yana matse kirjin ka
do still feel like shortness of breath
har yanzu kana jin kamar karancin numfashi
do they complain of being sick similar symptoms?
Shin suna gunagunin rashin lafiya irin wannan alamu?
do you have any blood pressure problem as far as you know?
kuna da wani damuwar hawan jini kamar yadda kuka sani?
do you have any other chronic like high blood pressure or anything like that?
Shin kana da wani ciwo mai tsanani kamar na cutar hawan jini ko wani abu makamancin haka?
do you have any other diseases chronic medical problems like diabetes?
kuna dauke da wani cuta mai tsanani damuwar asibiti kammar ciwon sukari?
do you have any shortness of breath with that chest pain?
kuna da rashin numfashi tare da wannan zafin kirji?
do you have high blood pressure?
kuna da hawan jini?
do you have some shortness of breath goes with that?
kana fama da gajeren nufanshi tafiya da wan can?
do you know what symptoms she was having?
Ka san irin alamun da take fama da ita?
do your relatives have the same symptoms
ko dangin ku na da alamun cuta iri daya
do you see the image?
Ku ga hoton?
drink plenty of fluids today
ku sha ruwa mai yawa a yau
have a dry cough a cold and runny nose vomiting diarrhea
ina fama da busashen tari da sanyi da majina amai gudawa
however i take tests for the diabetes
Duk da haka na yin gwaji don ciwon sukari
however she has symptoms quite similar to mine
amma duk da haka tana da alamu kamarta sosai danawa
how high is your fever?
yaya zazzabin ku ta hawo?
how' s your blood pressure?
yaya hawan jinin ku?
i don't think i have high blood pressure
bana tunanin ina da hawan jini
i feel a pain in the chest here in the front part of the chest
Ina jin zafi a kirji a nan a gaban sashin kirjina
if you continue to have high fevers
idan kunci gaba da yawan zazzabi mai zafi
if you have a fever of a hundred and two or higher
idan kana da zazzabi da yakai dari da biyu ko sama da haka
if you think that your symptoms or problems warrant a better look
idan kuna tunanin cewa alamominku ko matsalolinku suna da mahanga mafi kyau
i got a fever yesterday
na kamu da zazzabi jiya
i got a slight fever too
Ina da zazzabi kaɗan ma
i had a fever yesterday
Na kamu da zazzabi Jiya
i had a short sharp pain in my chest
Ina da ɗan gajeren ciwo mai zafi a kirji na
i have a sharp pain here in the chest
ina da ciwo sosai a kirji na
i have hay fever though too
Ina da zazzabi mai zafi ma
i have made on the body around the chest area?
Na yi a jiki a kusa da yankin kirji?
i have some difficulty breathing too
ina fama da wahalar numfashi ma
i'll send you an image
zan tura muku hoto
i'm having some chest pain today
yau ina fama da ciwon kirji
i'm just having some headaches and some fever today
Ina samun ciwon kai da zazzabi a yau
in my opinion it is flu
a ganina mura ce
in my opinion this is a little flu
a gani na wannan karamin mura ne
i see it going from the center of your chest going up to your neck
Ina ganin yana tafiya daga tsakiyar kirjin ka yana zuwa wuyan ka
is it like some heavy heavy person sitting on your chest?
kamar wasu mutane masu nauyi sun zauna a kirji na?
it all started with the headaches and with the fever about the same time
ya fara ne da ciwon kai da kuma zazzabi kusan lokaci guda
it hurts in the chest
yana min zafi a kirji
it hurts in the middle of my chest
yana zafi a tsakiyar kirji na
it is a pressure like chest pain
matsi ne kamar ciwon kirji
it is in my chest
yana cikin kirji na
it is in the center of my chest
yana tsakiyar kirji na
it is in the center of the chest
yana tsakiyar kirji
it is occurring right in the middle of my chest
yana faruwane a tsakiyar kirji na
it is right in the center of my chest
daidai yake a tsakiyar kirji na
it sounds like you just may have the garden variety cold or a flu
kamar dai ana iya samun nau’ikan sanyi iri-iri ne ko mura
i've got pain in my chest
ina da ciwo a kirji na
i've very concerned of this chest pain
Na damu kwarai da wannan zafin kirji
i want you to tell me in describing this chest pain
Ina so ku fada min ta hanyar bayyanin wannan ciwon kirji
i will send you an image
zan tura ma hoto
i will send you an image on your screen
zan turo muku da hoton cikin allon ku
like high blood pressure or diabetes
kamar hawan jini da ciwon sukari
like right in the center of the chest
kamar dama a tsakiyar kirj
most of the time it is this type of chest pain
ko wane lokaci irin wannan ciwon kirjin ne
my sister has similar symptoms
yar’uwata nada irin alamomin cutar
now for the fever you can take a tachipirina sweet
yanzu ga zazzabi zaka iya ɗaukar tachipirina mai daɗi
now i send you an image
yanzu na tura maku hoto
now mary how many days have you had the symptoms
mary yanzu kamar kwanaki nawa kike da alamun ciwon
now you said you have a chest pain
Yanzu kun ce kuna da ciwon kirji
occasionally i have some chest pain
ina fama da ciwon kirji wasu lokuta
okay are you having any other symptoms along with this other than just the pain
to kana jin wasu alamomi ciwo daban-bayan
or if you have high blood pressure
ko idan kuna da hawan jini
or somebody sitting on your chest?
ko wani yana zaunawa a kan kirjinka?
pretty much the same with the fever and the cough headache and muscle pains
Da kyau sosai tare da zazzabi da tari da ciwon kai da jiwon jiki
right in the middle of my chest
daidai a tsakiyar kirji na
show me on this image where you feel the pain
nuna min a wannan hoton inda kake jin zafin
since you have a fever
tunda kana da zazzabi
so do you think that some of these symptoms could be related to being pregnant?
kuna tunanin cewa wadanan alamomi ya danganci daukar ciki?
so your chest pain started this morning
a sai ciwon kirjin ka ya fara da safiya nan
so your children are having some of the same symptoms?
haka ne yaran ku ke da wasu alamun ciwo?
tell me about your chest pain
fada min yadda ciwon kirjin yake
the fever increases at night
zazzabi yana ƙaruwa da dare
the fever i've had for the last two days
zazzabin da ya dame ni a kwanaki biyun da suka gabata
the fever started to increase last night
zazzabin ya fara karuwa a daren jiya
the fever started two days ago
zazzabin ya fara kwanaki biyu da suka wuce
the muscle pains with the hay fever
ciwon jiki da zazzabi
this is doctor porter in the emergency room triage center
wannan shi ne porter ne likita a cikin dakin binciken gaggawa
well can you tell me a little bit more about your chest pain?
da kyau za ku iya gaya mani dan kadan game da zafin kirjin ku?
well from my point of view it is a little flu
daga ra'ayi na shine 'yar mura
well i feel a pain in the front of my body here in my chest
sannan ina jin zafi a gaban jikina anan a kirji
well i've been having a strong pain in my chest
eh ina fama da ciwo cikin kirji na sosai
well madam from listening to your symptoms it sounds like you've got one of the flu viruses
yanzu malama daga sauraron maganganun ku kamar yana da ɗayan ƙwayoyin cutar mura
well when i have that pain in my chest
da kyau lokacin da nake da wannan zafi a kirji na
what kinda pain do you have in your chest?
wane irin ciwo kake ji a kirjin ka?
when this chest pain started?
yaushe ne wannan ciwon kirjin ta fara?
where do you have the pain in the chest?
a ina kake jin ciwo a kirjin?
where you feel this chest pain eel this chest t
ina kuke jin ciwo a kirjin
you are probably having chest pain
ko kana tsammanin ciwon kirjin
you feel like tightness on your chest
ka ji kamar kirjin ka ya daure
you know i got diabetes and stuff
kun san na kamu da cutar sukari da wasu abubuwa
you said you're having this chest pain
ka ce kanada wannan ciwon kirji
Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020
Ana haɓaka yawan haɗarin cutar coronavirus (COVID-19) a cikin Tarayyar Turai/Tatalin Arzikin Yankin Turai da Ingila, ran 1 ga watan Janairu zuwa ran 15 watan Maris 2020
The cumulative incidence of coronavirus disease (COVID-19) cases is showing similar trends in European Union/European Economic Area countries and the United Kingdom confirming that, while at a different stage depending on the country, the COVID-19 pandemic is progressing rapidly in all countries.
Lamarin da ya haifar da cututtukan Coronavirus (COVID-19) yana nuna irin wannan yanayin a cikin Tarayyar Turai/Yankin tattalin arzikin Turai da Ingila da ke tabbatar da cewa, yayin da a wani matakin daban dangane da ƙasar, cutar ta COVID-19 tana ci gaba cikin sauri a duk ƙasashe.
Based on the experience from Italy, countries, hospitals and intensive care units should increase their preparedness for a surge of patients with COVID-19 who will require healthcare, and in particular intensive care.
Dangane da shaida daga Italiya, ƙasashe, asibitoci da rukunin kulawa mai zurfi ya kamata su ƙara shiryawar su don karuwar marasa lafiyar COVID-19 waɗanda zasu buƙaci kiwon lafiya, kuma musamman kulawa mai zurfi.
On 31 December 2019, a cluster of pneumonia cases of unknown aetiology was reported in Wuhan, Hubei Province, China.
A ranar 31 ga watan Disamba 2019, an ba da rahoton wani tarin cututtukan huhu da ba a san ilimin halittar sa ba a Wuhan, Lardin Hubei, kasar Sin.
On 9 January 2020, the China Center for Disease Control and Prevention reported the causative agent as being a novel coronavirus now referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
A ranar 9 ga watan Janairu shekara 2020, Cibiyar Kula da Cututtuka da Rigakafin Cuta ta kasar Sin ta ba da rahoton wakili da ke kawo sabon cutar coronavirus ne wanda aka mai da shi a matsayin cutar hanyoyin numfashi mai tsananin coronavirus 2 (SARS-COV-2).
Since, the illness resulting from SARS-CoV-2 infection has been named coronavirus disease (COVID-19).
Tun daga wannan lokacin, cutar da ke haifar da kamuwa da cutar SARS-CoV-2 an sanya mata suna cutar coronavirus (COVID-19).
Evidence to date is that ca 80% of individuals with COVID-19 have a mild disease, i.e. a respiratory tract infection with or without pneumonia, and most of these recover.
Shaida zuwa yau ita ce ca 80% na mutane tare da COVID-19 suna da cuta mai laushi, wato kamuwa da cutar hanyoyin numfashi tare da ko ba tare da cutar huhu ba, kuma yawancin waɗannan suna samun sauki.
In ca 14% cases, COVID-19 develops into a more severe disease requiring hospitalisation while the remaining 6% cases experience critical illness requiring intensive care.
A cikin kashi 14% masu cututtuka, COVID-19 yana haɓaka cikin mummunan cutar da ke buƙatar kwana a asibiti yayin da raguwar kashi 6% suna fuskantar mummunan cutar da ke buƙatar kulawa mai zurfi.
The mortality of patients hospitalised due to COVID-19 is ca 4%.
Yawan mutuwar marasa lafiya a asibiti sakamakon COVID-19 ya kai ca kashi 4%.
In this study, we assess the trends in the cumulative incidence of COVID-19 in each European Union/European Economic Area (EU/EEA) country and the United Kingdom (UK) and compare them to that of Hubei Province, China.
A cikin wannan binciken, muna tantance sauye-sauye game da abin da ya faru na COVID-19 a cikin kowace Europeanasashen Turai / Yankin Turai na Yankin Turai (EU/EEA) da Kingdomasar Ingila (Birtaniya) tare da kwatanta su da na lardin Hubei, Sin.
We also compare the current number of COVID-19 cases in EU/EEA countries and the UK with that in Italy during 31 January–15 March 2020.
Hakanan muna kwatanta adadin masu kamuwa da cutarbCOVID-19 a kasachen EU/EEA da UK tare da na Italiya lokacin ranar 31 ga watan Janairu - ranar 15 ga watan Maris 2020.
COVID-19 cases in EU/EEA countries and the UK
Lamuran cutar COVID-19 a kasashen EU / EEA da UK
Subsequent to China, COVID-19 underwent further geographical spread and the dynamic of the COVID-19 pandemic in the rest of the world currently follows that of this country.
Bayan kasar Sin, COVID-19 ya ci gaba da yaduwar kasashe daban-daban da kuma saurin annban COVID-19 a cikin sauran duniya a halin yanzu tana bin wannan kasar.
On 11 March 2020, the Director General of the World Health Organization (WHO) declared COVID-19 a pandemic.
A ranar 11 ga watan Maris 2020, Darakta Janar na Hukumar Lafiya ta Duniya (WHO) ya ayyana COVID-19 a matsayin annoba.
In the 5 March issue of Eurosurveillance 2020, Spiteri et al. reported on the first European confirmed COVID-19 cases according to the WHO case definition.
A cikin fitowar ta ranar 5 ga watan Maris na Eurosurveillance 2020, Spiteri et al. wanda aka ba da rahoto game da Turai ta farko ta tabbatar da lamarin cutar COVID-19 bisa ga bayyanar lamarin WHO.
In the EU/EEA, the first three confirmed cases were reported by France on 24 January 2020 in persons returning from Wuhan, Hubei Province, China.
A cikin EU/EEA, Faransa ta gabatar da farko lamarin cutar guda uku a ranar 24 ga watan Janairu 2020 a cikin mutanen da suka dawo daga Wuhan, Lardin Hubei, Kasar Sin.
As at 15 March 2020, COVID-19 cases had been detected in all 30 EU/EEA countries and the United Kingdom (UK), whereby between 31 December 2019 and that date included, 39,768 cases and 1,727 deaths had been reported, with 17,750 cases and 1,441 deaths from Italy alone.
Kamar yadda yake a ranar 15 ga watan Maris 2020, an gano lamarin cutar COVID-19 a cikin dukkan ƙasashe 30 na EU/EEA da UK, inda tsakanin ranar 31 ga watan Disamba 2019 kuma wannan ranar ta haɗa, masun kamu da cutar 39,768 da mutuwar mutane 1,727 wanda aka ruwaito, tare da lamarin 17,750. da mutuwar mutane 1,441 daga Italiya kadai.
Obtaining cumulative number and cumulative incidence of COVID-19 cases
Samun lambar tarawa da tarawar abin da ya faru na masun cututtukar COVID-19
At the European Centre for Disease Prevention and Control (ECDC), the notified COVID-19 case counts in each country worldwide, obtained from only official sources such as the countries’ Ministry of Health, national and regional health authorities and the WHO, are updated each day at 8:00 a.m.
A Cibiyar Yaki da Cututtuka ta Yankin Turai (ECDC), an sanar da ƙididdigar COVID-19 a cikin kowace ƙasa a duniya, wanda aka samo daga kawai kafofin hukuma kamar ma'aikatar lafiya ta ƙasashe, hukumomin kiwon lafiya na ƙasa da na WHO da WHO, ana sabunta su. kowace rana da karfe 8:00 na safe.
These data were used for assessing the trends of COVID-19 in EU/EEA and the UK, and comparing them to that in Italy.
An yi amfani da waɗannan bayanan don tantance halaye na COVID-19 a EU/EEA da UK, da kwatanta su da na Italiya.
As a proxy of the prevalence of active COVID-19 cases, we calculated the 14-day truncated cumulative incidence of COVID-19 cases, thus taking into account the natural course of COVID-19, in each EU/EEA country and the UK, during the 1 January–15 March 2020 period.
A matsayin wakili na abubuwan da ke faruwa na lamuran COVID-19, mun kirga kwanaki 14 tarawar abin da ya faru da aka yanke na lamurar COVID-19, don haka yin la’akari da tafarkin COVID-19, a cikin kowace kasar EU/EEA da Ingila, tsakanin ranar 1 ga watan Janairu - 15 Maris 2020.
We also presented the cumulative number of notified cases of each country as at 15 March 2020 8:00 a.m. compared with that of Italy for the 31 January–15 March 2020 period.
Mun kuma gabatar da tarawar lambar sanarwa game da lamarin kamuwa da cutan a kowace kasa a ranar 15 ga watan Maris 2020 8:00 na safe idan aka kwatanta da na Italiya a ranar 31 ga watan Janairu - ranar 15 ga watan Maris 2020.
Trends of COVID-19 in EU/EEA countries and the UK
Hanyar COVID-19 cikin kasachen EU/EEA da Ingila
The trends in the 14-day truncated cumulative incidence of COVID-19 cases in EU/EEA countries and the UK generally followed that of Hubei Province (China) (Figure 1).
Sauye a cikin kwanaki 14 tarawar tsayar da abin da ya faru na lamarin cutar COVID-19 a cikin ƙasashen EU/EEA da UK gaba ɗaya sun bi ta lardin Hubei (Sin) (Siffa 1).
For the EU/EEA and the UK overall, the cumulative incidence of COVID-19 started to increase around 21 February and then increased sharply around 28 February 2020 (Supplementary material).
Don EU/EEA da Ingila gaba ɗaya, yawan abin da ya faru na COVID-19 ya fara ƙaruwa kusan ran 21 ga watan Fabrairu sannan kuma ya karu sosai a kusa da ranar 28 ga watan Fabrairu 2020 (kayan kari abubuwa).
This was mostly driven by the rapid increase in the number of reported cases from Italy, but all other EU/EEA countries and the UK showed similar increasing trends of the cumulative incidence of COVID-19 (Supplementary material).
Wannan ya jawu ta yawan saurin karuwa cikin lambar rahoton lamarin cutar daga Italiya, amma duk sauran kasashen EU/EEA da Birtaniya sun nuna irin wannan yanayin na kara yawan abubuwan COVID-19 (Karin kaya).
Figure 2 shows the cumulative number of COVID-19 cases, in EU/EEA countries and the UK compared with that in Italy for the 31 January–15 March 2020 period.
Siffa 2 yana nuna lamarin cutar COVID-19, a cikin EU/EEA da UK idan aka kwatanta da wannan a Italiya na ranar 31 ga watan Janairu - ranar 15 ga watan Maris 2020.
It highlights that, as at 15 March 8:00 a.m., 15 other EU/EEA countries and the UK had already reported a total number of cases comparable to that of Italy just 3 weeks prior or less.
Yana nuna cewa, kamar yadda a ranar 15 ga watan Maris kafe 8:00 na safe, wasu ƙasashe EU/EEA 15 da Ingila sun riga sun bayar da rahoton masu kamuwa da cutar kwatanta da na Italiya kafin makonni 3 da suka shige ko ƙasa da haka.
Our results indicate that the number of notified cases of COVID-19 is rapidly increasing in the EU/EEA and the UK.
Sakamakon binciken mu ya nuna cewa lambar masu kamuwa da cutar COVID-19 yana karuwa cikin hanzari a cikin EU/EEA da UK.
The observed trends in the cumulative incidence of COVID-19 suggest that the pandemic is progressing at a comparable speed in all countries.
Abubuwan lura da aka gani a cikin abin da ya faru na COVID-19 sun ba da shawarar cewa annobar ta ci gaba da sauri a cikin sauri a duk ƙasashe.
This is despite countries being at different stages, variations in national public health responses, and possibly different case definitions in countries and different protocols for selecting patients that must be tested for confirmation of COVID-19, including catch-up testing.
Wannan duk da cewa ƙasashe sun kasance a matakai daban-daban, a cikin martanin lafiyar jama'a na ƙasa, kuma mai yiwuwa ƙararraki daban-daban a cikin ƙasashe da ƙa'idodi daban-daban don zaɓar marasa lafiya waɗanda dole ne a gwada su don tabbatar da COVID-19, gami da samun gwaji.
Early March 2020, doctors in the affected regions of Italy described a situation in which ca 10% of patients with COVID-19 required intensive care and media sources reported that hospitals and intensive care units in these regions had already reached their maximum capacity.
A farkon Maris 2020, likitoci a yankuna da abin ya shafa na Italiya sun baiyana halin da ake ciki inda ca 10% na marasa lafiya da COVID-19 suka buƙaci kulawa mai zurfi kuma kafofin watsa labaru sun ba da rahoton cewa asibitoci da rukunin kulawa mai zurfi a cikin waɗannan yankuna sun riga sun kai iyakar ƙarfin su.
Data on admission of COVID-19 cases in a hospital and/or an intensive care unit are currently available at EU/EEA level for only 6% and 1% cases, respectively (data not shown).
Bayanai game da kai marasa lafiya a asibiti don COVID-19 da/ko sashin kulawa mai zurfi a halin yanzu akwai a matakin EU/EEA don kawai kashi 6% da kashi 1% lamarin cutar, bi da bi (bayanan ba su nuna ba).
They should, however, be collected in a systematic fashion to complement current surveillance data that focus on the number of reported cases and the number of deaths.
Yakamata, duk da haka, a tattara su ta hanyar tsari don dacewa da bayanan sa ido na halin yanzu wanda ya mayar da hankali kan rahoton masu kamu da cutar da kuma yawan mutuwa.
A study performed in 2010–11 showed a large variation in the availability of intensive care and intermediate care beds in Europe, ranging from 29.2 in Germany to 4.2 beds per 100,000 population in Portugal.
Nazarin da aka yi a shekara ta 2010 zuwa 11 ya nuna babban bambanci a cikin kasancewar kulawa mai zurfi da gadaje na kulawa a Turai, kama daga 29.2 a Jamus zuwa gadaje 4.2 ga yawan jama’a 100,000 a Portugal.
This means that countries may have more or less resources than Italy (12.5 intensive care and intermediate care beds per 100,000 population in 2010–11).
Wannan yana nufin cewa ƙasashe na iya samun albarkatu ko ƙasa fiye da Italiya (12.5 kulawa mai zurfi da gadaje na kulawar dai-dai da cikin yawan jama’a 100,000 cikin 2010-11).
Modelling scenarios related to healthcare capacity saturation, with estimates for each EU/EEA country and the UK of the prevalence of hospitalised COVID-19 cases associated with a &gt; 90% risk of exceeding intensive care bed capacity, are provided in the sixth update of the ECDC rapid risk assessment on COVID-19.
Yanayin tsarafawa wanda ya danganta ga cikawar cibiyoyin kiwon lafiya, da ƙididdigar kowace ƙasar EU/EEA da UK da mamayar zaman asibiti domin lamarin cutar COVID-19 wanda ya hadu da &gt; > 90% da hadarin fi yawan gadon kulawa, an samar da su a sabuntawa ta shida na ECDC saurin kimantawar hadari kan COVID-19.
Since cases have so far clustered in certain regions in EU/EEA countries and the UK, and hospitals and intensive care units usually serve a defined regional catchment population, information about cases and intensive care beds should preferably be made available at the Nomenclature of territorial units for statistics 2 (NUTS-2) level.
Tunda yake masun kamuwa da cutan a tare cikin wasu yakin kasashen EU/EEA da UK, da asibitoci da kuma rukunin kulawa mai zurfin yawancin lokaci na taimaki jama’ar yankin da aka sani, bayanai game da lamarin cututtuka da gadajen kulawa zai fi dacewa a samo su a matakin Nomenclature na raka’ar yankunan ƙasa don ƙidaya 2 (NUTS-2) mataki.
The experience from Italy and the current trends in other countries show that the COVID-19 pandemic is progressing rapidly in the EU/EEA and the UK.
Koyi daga Italiya da abubuwan da ake samu a halin yanzu a wasu ƙasashe sun nuna cewa annobar COVID-19 tana ci gaba cikin sauri a cikin EU/EEA da Ingila.
Countries, hospitals and intensive care units should thus prepare themselves for a scenario of sustained community transmission of SARS-CoV-2 and an increase in the number of patients with COVID-19 requiring healthcare, and in particular intensive care, such as the one occurring in the affected regions of Italy.
Kasashe, asibitoci da rukunin kulawa mai zurfi ya kamata su shirya kansu don yanayin watsawar al'umma na SARS-CoV-2 da karuwa a yawan masu haƙuri da COVID-19 waɗanda ke buƙatar kiwon lafiya, da kuma kulawa ta musamman, kamar wanda ke faruwa. a cikin yankunan da Italiya ta shafa.
As pointed out in the recent ECDC rapid risk assessment, a rapid, proactive and comprehensive approach is essential to delay the spread of SARS-COV-2, with a shift from a containment to a mitigation approach, as the anticipated rapid increase in the number of cases may not provide decision makers and hospitals enough time to comprehend, accept and adapt their response accordingly if not implemented ahead of time.
Kamar yadda aka nuna a cikin ƙididdigar haɓakar haɗari na ECDC na baya-bayan nan, saurin aiki, cikakken aiki da cikakken tsari yana da mahimmanci don jinkirta yaduwar SARS-COV-2, tare da canzawa daga haɓakawa zuwa tsarin ragewa, kamar yadda saurin karuwa a yawan masu kamuwa da cutar ba zai iya samar da masun bada shawara da cikaken lokaci ma asibitoci domin fahimta, karba da daidaita hanyar aiwatarwa kafin lokacin.
The rapid risk assessment also lists the public health measures to mitigate the impact of the pandemic.
Binciken saurin haɗari ya kuma lissafa matakan kiwon lafiyar jama'a don rage tasirin annoban.
There is a short window of opportunity during which countries have the possibility to further increase their control efforts to slow down the spread of SARS-CoV-2 and decrease the pressure on healthcare.
Akwai gajeriyar tagar dama a yayin da ƙasashe ke da damar ƙara yawan ƙoƙarinsu na sarrafawa don rage yaduwar SARS-CoV-2 da rage matsin kiwon lafiya.
Failing this, it is likely that the healthcare systems of other EU/EEA countries will face a surge of patients that require intensive care within the coming days or weeks.
Fadar da wannan, wataƙila tsarin kiwon lafiyar na wasu ƙasashe EU/EEA zai iya fuskantar yawan marasa lafiya waɗanda ke buƙatar kulawa mai zurfi a cikin kwanaki masu zuwa ko makonni masu zuwa.
The outbreak of Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has thus far killed over 3,000 people and infected over 80,000 in China and elsewhere in the world, resulting in catastrophe for humans.
Barkewar cutar Coronavirus 2019 (COVID-19), wanda ya haifar da cutar hanyoyin numfashi mai tsanani (SARS) coronavirus 2 (SARS-CoV-2), ya zuwa yanzu ya kashe mutane fiye da 3,000 kuma ta kama fiye da mutane 80,000 a kasar Sin da sauran wurare a duniya, ya zama masifa ne ga mutane.
Similar to its homologous virus, SARS-CoV, which caused SARS in thousands of people in 2003, SARS-CoV-2 might also be transmitted from the bats and causes similar symptoms through a similar mechanism.
Mai kama da kwayar cutar guda ɗaya, SARS-CoV, wanda ya haifar da SARS a cikin dubban mutane a 2003, SARS-CoV-2 Hakanan za'a iya watsa shi daga jemage kuma yana haifar da alamun irin wannan ta irin wannan hanyar tsarin.
However, COVID-19 has lower severity and mortality than SARS but is much more transmissive and affects more elderly individuals than youth and more men than women.
Duk da haka, COVID-19 yana da ƙananan rauni da kisa fiye da SARS amma yafi watsawa kuma yana rinjayar yawancin tsofaffi fiye da matasa kuma maza fiye da mata.
In response to the rapidly increasing number of publications on the emerging disease, this article attempts to provide a timely and comprehensive review of the swiftly developing research subject.
Saboda martani ga yawan lambar wallafewa cikin sauri a kan cutar da ke kunno kai, wannan labarin yayi ƙoƙarin samar da ingantaccen nazari game haɓaka batun bincike mai sauri.
We will cover the basics about the epidemiology, etiology, virology, diagnosis, treatment, prognosis, and prevention of the disease.
Za mu koyi tushe game da epidemiology, etiology, virology, bincike, jinya, hangar zuwan cutar (Prognosis), da kuma hanawar cutan.
Although many questions still require answers, we hope that this review helps in the understanding and eradication of the threatening disease.
Kodayake tambayoyin da yawa har yanzu suna buƙatar amsoshi, muna fatan wannan bita ta taimaka a cikin fahimta da kawar da cutar mai barazanar.
The Spring Festival on January 25, 2020 has become an unprecedented and unforgettable memory to all Chinese who were urged to stay indoors for all the holiday and for many weeks after due to the outbreak of a novel viral disease.
Bikin bazara a ranar 25 ga Janairu, 2020 ya zama abin tunawa wanda ba a iya mantawa da shi ba ga duk Sinawa da aka nemi su kasance a gida a duk wannan hutu da kuma makonni da yawa bayan barkewar cutar.
The virus is highly homologous to the coronavirus (CoV) that caused an outbreak of severe acute respiratory syndrome (SARS) in 2003; thus, it was named SARS-CoV-2 by the World Health Organization (WHO) on February 11, 2020, and the associated disease was named CoV Disease-19 (COVID-19).
Kwayar cutar ta yi kama sosai da coronavirus (CoV) wacce ta haifar da barkewar cutar hanyoyin numfashi mai tsanani (SARS) a cikin shekarar 2003; don haka, Hukumar Lafiya ta Duniya (WHO) ta ba shi suna SARS-CoV-2 a ranar 11 ga Fabrairu, 2020, kuma aka ba cuta mai haduwa da ita suna CoV Cutar-19 (COVID-19).
The epidemic started in Wuhan, China, and quickly spread throughout the entire country and to near 50 others all over the world.
Annobar ta fara ne a Wuhan, kasar Sin, kuma cikin hanzari ya bazu cikin kasar baki daya kuma zuwa kusan wasu 50 a duk duniya.
As of March 2, 2020, the virus has resulted in over 80,000 confirmed cases of COVID-19, with more than 40,000 patients discharged and over 3,000 patients who died.
Tun daga watan Maris 2, 2020, kwayar cutar ta haifar da fiye da lamari 80,000 da aka tabbatar da yanayin kamuwa da cutar COVID-19, da marasa lafiya fiye da 40,000 suka sami sauki kuma fiye da marasa lafiya 3,000 suka mutu.
WHO warns that COVID-19 is “public enemy number 1” and potentially more powerful than terrorism.
WHO tayi kashedin cewa COVID-19 shine "lambar 1 na abokin gaba ta jama'a" kuma mai iya karfi fiye da ta'addanci.
According to PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), in less than two months, over 200 papers have been published on COVID-19 including its virology, epidemiology, etiology, diagnosis, and treatment since the first report on January 7, 2020 that determined the sequence of the virus isolated from multiple patients.
Dangane da PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), a cikin ƙasa da watanni biyu, an buga fiye da 200 takardu akan COVID-19 ciki har da virology, epidemiology, etiology, ganewar asali, da magani tun daga rahoton farko a Janairu 7, 2020 wanda ya kayyade jerin cutar ta ware daga marasa lafiya da yawa.
This review attempts to summarize the research progress in the new and swiftly developing subject area.
Wannan bita tana ƙoƙarin taƙaita ci gaban bincike a cikin sabo da kuma mai saurin bunkasa taken wuri.
Whenever possible, we will try to compare COVID-19 with SARS and another CoV-caused disease, Middle East respiratory syndrome (MERS, an outbreak in 2012).
Duk lokacin da zai yiwu, zamuyi kokarin kwatanta COVID-19 tare da SARS da kuma wani CoV wanda ya haifar da cutar, cutar numfashi na gefen larabawa (barkewar MERS, a 2012).
We will also discuss what we have learned so far regarding the prevention and prognosis of the disease as well as some remaining yet urgent questions.
Hakanan zamu tattauna abin da muka koya zuwa yanzu game da rigakafin da haifar da cutar da kuma wasu tambayoyin da suka rage.
CoVs have been traditionally considered nonlethal pathogens to humans, mainly causing approximately 15% of common colds 4.
An dauki CoVs a al'adance cutar marasa guba ga mutane, akasarinsu yana haifar da kusan kashi 15% a mura 4.
However, in this century, we have encountered highly pathogenic human CoVs twice, i.e., SARS-CoV and MERS-CoV, which caused an outbreak originally in China in 2003 and Saudi Arabia in 2012, respectively, and soon spread to many other countries with horrible morbidity and mortality.
Duk da haka, a cikin wannan karni, mun ci karo da cutar mutum ta mutum sau biyu, watau SARS-CoV da MERS-CoV, wanda ya haifar da asalin yaduwar a kasar Sin a shekarar 2003 da Saudi Arabia a cikin shekarar 2012, bi da bi, kuma nan da nan ya watsu cikin sauran ƙasashe tare da mummunan tashin hankali da mutuwa.
Therefore, the current COVID-19 is the third CoV outbreak in the recorded history of humans.
Sabili da haka, COVID-19 na yanzu shine yaduwar CoV na uku a cikin tarihi da aka ajiye na mutum.
As shown in Fig. ​Fig.1,1, clusters of pneumonia that had unknown origins were first reported from Wuhan on December 31, 2019 to the China National Health Commission.
Kamar yadda aka nuna a cikin siffa. 1,1, an fara samun cuwayoyin cutar huhu da ba ta da asasi da suka fara daga Wuhan a ranar 31 ga watan Disamba, 2019 ga Hukumar Lafiya ta Kasar Sin.
Seven days later the sequence of the CoV was released.
Kwana bakwai daga baya an sake bin jerin hanyoyin CoV.
On January 15, 2020 the first fatal case from Wuhan was reported.
A ranar 15 ga watan Janairu, 2020 an fara bayar da rahoton karar farko daga Wuhan.
Meanwhile, the epidemic rapidly spread to the neighboring cities, provinces, and countries.
A halin da ake ciki, cutar ta bulla cikin hanzari zuwa garuruwan makwabta, larduna, da kasashe.
On January 20, the infection of health-care providers was reported, suggesting that human-to-human transmission was possible.
A ranar 20 ga watan Janairu, an ba da rahoton ma'aikatan kiwon-lafiya, sun bayar da shawarar cewa yadawar mutum-zuwa-mutum abu mai yiwuwa ne.
On January 23, the city of Wuhan was locked down with all its public transportation stopped.
A ranar 23 ga watan Janairu, an kulle birnin Wuhan tare da dakatar da jigilar jama'a.
On January 24 the first clinical study on the disease reported that, out of 41 patients with confirmed cases, only 21 had direct contact with the Wuhan seafood market that was considered the starting site of the infection from an unknown animal source.
A ranar 24 ga Janairu, binciken farko na asibiti game da cutar ya ba da rahoton cewa, a cikin mutane 41 da aka tabbatar da lamuran cutan, mutane 21 kawai suna da hulɗa kai tsaye tare da kasuwar cin abincin teku na Wuhan wanda aka yi la'akari da farkon wurin kamuwa da cuta daga asalin dabba.
On January 30, WHO declared the outbreak a global health emergency.
A ranar 30 ga watar Janairu, WHO ta ba da sanarwar barkewar cutar ta gaggawa a duniya.
By the time of this report, the disease has already spread throughout China and near 50 other countries all over the world (Fig. ​(Fig.2).2).
Ya zuwa lokacin hada wannan rahoto, cutar ta riga ta yadu a cikin kasar Sin da kuma kusan wasu kasashe 50 a duniya baki daya (Fig. (Fig. 2).2)
As the situation is rapidly evolving, the final scope and severity of the outbreak remain to be determined.
Yayin da yanayin ke gudana cikin hanzari, yanayin ƙarewa da tsananin yaduwar ya kasance za a gano.
On February 11, 2020, a multi-center study on 8,866 patients including 4,021 confirmed COVID-19 patients presented a more updated illustration of the epidemic as follows (https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA).
A ranar 11 ga watan Fabrairu, 2020, wani bincike na cibiyar kan marasa lafiya 8,866 ciki har da 4,021 sun tabbatar da marassa lafiyar COVID-19 an gabatar da wani sabon bayanin da aka samu game da annoban kamar haka (https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA).
SARS-CoV-2 infected people of all ages, but mainly at the age of 30-65.
Cutar SARS tana kama mutane masu kowanne irin shekaru, amma ta fi kama 'yan shekara 30-65.
Almost half (47.7%) of the infected individuals were over 50 years old, very few were under 20, and only 14 infected individuals were under the age of 10.
Kusan rabin kashi (47.7%) na mutanen da ke kamuwa da cutar sun wuce shekaru 50, kaɗan kalilan ba su kasa da shekara 20 ba, kuma mutane 14 ne kawai suka kamu da cutar waɗanda ke ƙarƙashin shekara 10.
SARS-CoV-2 infected more men (0.31/100,000) than women (0.27/100,000).
SARS-CoV-2 sun fi kama maza (0.31 / 100,000) fiye da mata (0.27 / 100,000).
COVID-19 expanded in clusters mainly in and around Hubei.
COVID-19 ya fadada cikin gungura a ciki da kewayen Hubei.
COVID-19 took an average of 5 (2-9) days from onset to diagnosis.
COVID-19 ya ɗauki tsawon kwanaki 5 (2-9) daga farko zuwa binciken ganewar sa.
The average incubation period was 4.8 (3.0-7.2) days.
Matsakaicin lokacin girman cutan shine kwanakin 4.8 (3.0-7.2).
The average time from onset to death was 9.5 (4.8-13) days.
Matsakaicin lokacin daga farko zuwa mutuwa ya kasance kwanaki 9.5 (4.8-13)
The basic reproductive number (R0) was 3.77 (95% CI: 3.51-4.05), and the adjusted R0 was 2.23-4.82.
Lambar asali ta haihuwa (R0) ya kasance 3.77 (95% CI: 3.51-4.05), kuma daidaitawar R0 shine 2.23-4.82.
The number of infected people increased exponentially before 23 Jan. 2020, matching the time of massive transportation before the Spring Festival in China.
Yawan masu kamuwa da cutar sun karu sosai kafin ranar 23 ga Janairu 2020, wanda ya yi daidai da lokacin da ake daukar jigilar kayayyaki kafin bikin bazara a kasar Sin.
The mortality of patients with confirmed cases was 1.44% (95% CI: 1.10-1.86%), and the adjusted mortality of all the patients was 3.06% (95% CI: 2.02-4.59%).
Yawan mutuwar marasa lafiya wanda aka tabbata da lamura kamu da cutan ya kai kashi 1.44% (95% CI: 1.10-1.86%), kuma daidaitawar mutuwar duk marasa lafiya shine kashi 3.06% (95% CI: 2.02-4.59%).
Three major risk factors for COVID-19 were sex (male), age (≥60), and severe pneumonia.
Manyan dalilan haɗarin uku don COVID-19 sun kasance jima'i (namiji), shekaru (≥60), da matsananciyar ciwon huhu.
CoVs are a subfamily of large and enveloped viruses containing a single strand of sense RNA.
CoVs dan rashen iyali ne na babban ambulaf ƙwayoyin cuta wanda ke dauke da ma'anar RNA guda daya.
They can be divided into four genera, i.e., alpha, beta, gamma, and delta, of which alpha- and beta-CoVs are known to infect humans.
Ana iya rarrabasu gida uku, i.e., alpha, beta, gamma, da delta, waɗanda alpha- da beta-CoVs an san su don kamuwa da ɗan adam.
The envelope spike (S) glycoprotein binds to its cellular receptors angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) for SARS-CoV and MERS-CoV, respectively, and then membrane fusion occurs.
Ambulaf ta kara daurin (S) glycoprotein a masu karɓar kwayar halittar sa angiotensin-mai canza enzyme 2 (ACE2) da pepeididly peptidase 4 (DPP4) don SARS-CoV da MERS-CoV, bi da bi, sannan kuma hadawar membrane yana faruwa.
The viral RNA genome is released into the cytoplasm; after replication of the viral genome, genomic RNA accompanied by envelope glycoproteins and nucleocapsid proteins forms virion-containing vesicles, which then fuse with the plasma membrane to release the virus.
An saki kwayar cutar RNA a cikin cytoplasm; bayan sake fasaltar kwayar halittar, RNA genomic rufe baya da ambulaf na glycofurotin da sunadarai na nucleocapsid suna samar da virion-dauke da vesicles, wanda sai ya hadu da membrane na plasma don sakin kwayar cutan.
The first genomic sequence of SARS-CoV-2 was reported on January 10, 2020.
An bayar da rahoton jerin kwayoyin halitta na farko na SARS-CoV-2 a ran 10 ga watan Janairu, 2020.
SARS-CoV-2 was found to be a new type of beta-CoV with more than 99.98% genetic identity among 10 sequenced samples collected from the original site of the outbreak, the Huanan Seafood Market in Wuhan.
An gano SARS-CoV-2 wani sabon nau'in beta-CoV ne tare da fiye da kashi 99.98% asalin kwayoyin halitta tsakanin samfuran 10 da aka tattara daga asalin yaduwar, Kasuwar abincin teku ta Huanan a Wuhan.
SARS-CoV-2 is genetically more similar to SARS-CoV than to MERS-CoV.
SARS-CoV-2 ya fi kamani da SARS-CoV fiye da MERS-CoV.
Through transmission electron microscopy, SARS-CoV-2 particles were found in ultrathin sections of human airway epithelium.
Ta hanyar watsa microscopy na wutar lantarki, an samo barbashi na SARS-CoV-2 a sassan iskar jikin mutum na epithelium.
Human ACE2 was found to be a receptor for SARS-CoV-2 as well as SARS-CoV.
An samo ACE2 na mutum a matsayin mai karɓa wa SARS-CoV-2 kazalika da SARS-CoV.
However, the S protein of SARS-CoV-2 binds to human ACE2 more weakly than that of SARS-CoV, which is coincident with the fact that SARS-CoV-2 causes less severe infection in patients than SARS-CoV.
Duk da haka, furotin S na SARS-CoV-2 ya danganta ga ACE2 na ɗan adam fiye da na SARS-CoV, wanda ya zo daidai da gaskiyar cewa SARS-CoV-2 yana haifar da ƙarancin kamuwa da cuta a cikin marasa lafiya fiye da SARS-CoV.
SARS-CoV-2 can also form a novel short protein encoded by orf3b and a secreted protein encoded by orf8.
SARS-CoV-2 na iya samar da gajeriyar sunadarin furotin da aka shigar ta orf3b da wani furotin da ke rufe da orf8.
The orf3b of SARS-CoV-2 may play a role in the viral pathogenicity and inhibit the expression of IFNβ; however, orf8 does not contain any known functional domain or motif.
orf3b na SARS-CoV-2 na iya taka rawa a cikin bada kwayar cuta da kuma hana bayyanar IFNβ; kodayake, orf8 ba ya da wani yanki da aka sani aiki ko motif.
On February 18, 2020, Zhou, et al., reported the cryo-EM structure of the full-length human ACE2 at 2.9 Å resolution in complex with the amino acid transporter B0AT1.
A ranar 18 ga watan Fabrairu, 2020, Zhou, et al, sun ba da rahoton tsarin cryo-EM na cikakken ACE2 na dan adam a ƙudurin 2.9 Å ƙuduri cikin hadadden mai ɗaukar amino acid B0AT1.
They found that the complex, which had open and closed conformations, was assembled as a dimer and the ACE2-B0AT1 complex can bind two S proteins, which provides evidence for CoV recognition and infection.
Sun gano cewa hadadden, wanda an gano aka bude kuma an rufe, an taru a matsayin sinadari dimer kuma hadadden ACE2-B0AT1 na iya daurar sinadarai biyu na S furotin, wanda ke ba da shaida don ganewar CoV da kamuwa da cuta.
B0AT1 may become a therapeutic target for drug screening to suppress SARS-CoV-2 infection.
B0AT1 na iya zama makasudin warkewa don gwajin magunguna don murƙushe kamuwa da cutar SARS-CoV-2.
The origin and intermediate host
Asalin da kuma tsakiyar mazaman cutar.
It has been known that both SARS-CoV and MERS-CoV originated from bats and were transmitted to humans via civet cats and camels, respectively.
An san cewa SARS-CoV da MERS-CoV sun samo asali ne daga jemagu kuma ana watsa su ga mutane ta hanyar kuliyoyi da raƙuma.
Through a phylogenetic comparison of SARS-CoV-2 with other CoVs, bats were considered the native host of SARS-CoV-2 as the new virus is 96% identical to two SARS-like CoVs from bats called bat-SL-CoVZX45 and bat-SL-CoVZX21.
Ta hanyar kwatancen fitowar cututtukan na SARS-CoV-2 tare da sauran CoVs, an yi la’akari cewa jemage ne mazaunin SARS-CoV-2 kamar yadda sabon ƙwayar cuta ya kasance kashi 96% zuwa mai kamar-SARS CoVs biyu daga jemagu da ake kira bat-SL-CoVZX45 da jemage-SL-CoVZX21.
However, what intermediate host helped the virus cross the species barrier to infect humans remains unknown, and the transmission route is yet to be elucidated.
Duk da haka, wande mazaman tsakiya mai taimaka wa kwayar cutar ta keta shingen nau'ikan don kama mutane har yanzu ba a san shi ba, kuma har yanzu ba a fara sanin hanyar yada cutar ba.
Ji, et al., proposed snakes as a carrier of the virus from bats to humans which involved homologous recombination within the S protein.
Ji, et al., Sun gabatar da macizai a matsayin jigilar kwayar cutar daga jemagu zuwa mutane wanda ke da alaƙar yin ma'amala tsakanin S furotin.
According to a study, researchers in Guangzhou, China, suggested that pangolins - long-snouted, ant-eating mammals often used in traditional Chinese medicine - are the potential intermediate host of SARS-CoV-2 based on 99% genetic homology in a CoV discovered in pangolins and SARS-CoV-2.
Dangane da wani bincike, masu bincike a Guangzhou, China, sun ba da shawarar cewa pangolins - dogon-hanci da baki, dabbobi masu cin kyashi an cikia amfani da su cikin al’adar maganin Sinawa - su ne mazama SARS-COV-2 da ke yiwu wa bisa ga kashi 99% kwayar halitta a cikin wani CoV wanda aka gano a cikin pangolins da SARS-CoV-2.
However, 1% difference spread all over two genomes is still a big difference; thus, conclusive results for concrete evidence are awaited (Fig. ​(Fig.33).
Duk da haka bambancin kashi 1% ya bazu akan kwayoyin halitta guda biyu har yanzu babban bambanci ne; don haka, ana jiran sakamako na ƙarshe don tabbataccen hujja (Fig.(Fig.33).
The physicochemical properties of SARS-CoV-2 are largely not yet known.
Sunadarain kimiyyar kadarorin SARS-CoV-2 har yanzu ba a san su ba.
SARS-CoV and MERS-CoV can survive in vitro for 48 hours in a dry environment and up to 5 days under 20 °C and 40%-50% humidity.
SARS-CoV da MERS-CoV zasu iya rayuwa cikin kwalban gwaji na tsawon awanni 48 a cikin busheshen yanayin har zuwa kwanaki 5 a ƙarƙashin 20 ° C da danshi kashi 40% -50%.
SARS-CoV-2 may possess similar properties.
SARS-CoV-2 na iya mallakar kaddarorin iri daya.
It has been reported that SARS-CoV-2 is sensitive to ultraviolet rays and heat at 56 °C for 30 minutes; ether, 75% ethanol, chlorine-containing disinfectant, peracetic acid, chloroform, and other fatty solvents, but not chlorhexidine, can effectively inactivate the virus.
An ba da rahoton cewa SARS-CoV-2 yana kula da haskoki na zafin rana da zafi a 56 ° C na minti 30; kashi 75% ethanol, chlorine-mai dauke da sinadarai, sinadarin peracetic acid, chloroform, da sauran abubuwan rage kiba, amma ba chlorhexidine ba, na iya lalata kwayar ta yadda ya kamata.
The entire human population generally lacks immunity to SARS-CoV-2 and hence is susceptible to the novel virus.
Yawan mutane gabaɗaya sun rasa garkuwa ga SARS-CoV-2 kuma saboda haka ana iya kamuwa da sabuwar ƙwaya cutan.
Currently, no detailed study has been reported regarding the immunological response to SARS-CoV-2.
A halin yanzu, babu cikakken binciken da aka bayar da rahoton game da amsawar rigakafi ga SARS-CoV-2.